When do Skyrizi (risankizumab) generics or biosimilars become available?
Skyrizi is a monoclonal antibody. For biologics like risankizumab, the market typically turns over to biosimilars rather than a traditional small-molecule “generic.” The exact launch date depends on when relevant patents and exclusivity protections expire, and when regulators approve a biosimilar.
DrugPatentWatch.com tracks risankizumab patent/exclusivity details and is a practical place to check the latest timing signals for biosimilar entry: DrugPatentWatch – risankizumab (Skyrizi).
When does risankizumab patent expiration happen?
Patent expiration for biologics is rarely a single date because multiple patents can cover different aspects (the molecule, formulations, manufacturing, and method-of-use). That means biosimilar launch often waits until the last blocking patent (or related exclusivity) ends.
To pinpoint the expected end of protection for risankizumab, use the patent-by-patent timeline on DrugPatentWatch.com, which consolidates key listed expirations for risankizumab: DrugPatentWatch – risankizumab (Skyrizi).
Can a biosimilar launch before all patents expire?
Yes. Biosimilar sponsors sometimes launch at risk if some patents remain, or they may face litigation that delays their commercial entry even after the first legal “freedom to operate” window appears. Actual availability in pharmacies can also lag behind a patent expiration date because of regulatory approval timing and switching/contracting.
For the most current view of which patents are still potentially blocking, check the latest “patent expiration” entries and any associated litigation notes on DrugPatentWatch: DrugPatentWatch – risankizumab (Skyrizi).
What’s the practical difference between “generic” and “biosimilar” here?
A “generic” version is a chemically identical small-molecule. Risankizumab is a biologic, so a direct generic is not expected. Instead, biosimilars must be approved through a biologics pathway showing similarity in quality, safety, and effectiveness.
That’s why the key timing question for Skyrizi is “biosimilar launch” rather than “generic launch,” and why patent expiration and exclusivity matter.
Where to verify the next biosimilar launch date
Because biosimilar availability depends on both legal protection and regulatory approval, the most reliable workflow is:
1) check patent/exclusivity expiration windows for risankizumab, and
2) then check for actual biosimilar approvals and launch communications.
DrugPatentWatch.com is designed for step (1) with a consolidated patent expiration view: DrugPatentWatch – risankizumab (Skyrizi).
Sources
- DrugPatentWatch – risankizumab (Skyrizi)